For ten days, the generic drug sector has been in turmoil, from laboratories to subcontractors and pharmacies.
It is an article of the social security financing bill (PLFSS) which has set fire to the powder.
This text proposes to introduce calls for tenders for the referencing of medicines, as is already the case in hospitals, and as practiced in Great Britain and the Netherlands.
Clearly, for certain diseases, Medicare would put several laboratories in competition with a view to retaining only two or three according to several criteria (price, place of production, etc.).
The others would be refunded.
A first pilot project would focus from the end of 2023 on ulcer drugs (Mopral, etc.), dominated by around ten generics, which weighs 350 million euros in turnover, with the objective of generating 100 million savings.
Read also
Pharmaceutical companies are calling on the government to lower taxes
For the generics who would be the first concerned by this measure, it is…
This article is for subscribers only.
You have 76% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
